SAO PAULO, March 13, 2026, 11:30 AM BRT.
Shares of Banco Bradesco traded flat in the U.S. on Friday, as investors digested news that the Brazilian lender’s shareholders gave the green light to a 6.67 billion reais capital injection—boosting stock capital but not adding any new shares. As of 11:13 a.m. BRT, the ADRs ticked up 0.1% to $3.66.
This matters right now: Bradesco’s capital jumps to 93.77 billion reais from 87.1 billion, just before shareholders weigh in on a separate healthcare reorganization set for March 31—the bank’s next big corporate move. The boost draws from reserves on the balance sheet, not a fresh share sale, so the amount of shares stays exactly the same—only internal funds are shifted.
According to final voting maps filed March 11, shareholders cleared Bradesco’s 2025 accounts and signed off on 2026 management pay set at 873 million reais, with another 36.95 million reais going toward the pension plan. The legal reserve tapped for the move is a profit reserve the bank already carried on its balance sheet.
Bradesco barely moved in New York, trailing its rivals. Itaú Unibanco’s ADR added 1.4%, Santander Brasil picked up 0.9%, but Bradesco stayed roughly unchanged.
During Bradesco’s earnings call on Feb. 6, Chief Executive Marcelo Noronha reported that return on equity hit 15.2% in the fourth quarter, finally topping the bank’s cost of capital for the first time in several quarters. “We expect to continue improving our ROE for the coming quarters,” Noronha said, calling the recovery a gradual process.
Noronha hinted that management saw the stock rally as overdone. Speaking in an interview that day, he noted Bradesco shares had surged 104% from Dec. 31, 2024, to Feb. 4, but predicted “some of the valuation” would be lost as analysts update their models for the 2026 outlook. Still, he said the bank plans to continue pouring money into technology to boost competitiveness.
Bradesco’s next big step comes March 31, when it’s set to ask shareholders to sign off on a partial spin-off of Bradseg—part of a broader push to fold its healthcare operations into Odontoprev. Back in February, Chairman Luiz Carlos Trabuco Cappi called the overhaul an effort to “enhance quality and efficiency” and ensure “value creation for all.” If approved, Bradesco says the merged group would represent a healthcare ecosystem pulling in 52 billion reais in revenue and netting 3.6 billion reais, with improved access to capital markets. Securities and Exchange Commission
Still, nothing’s locked in yet. The healthcare transaction faces hurdles—a few more shareholder nods, plus regulatory sign-off—while Odontoprev holders can still opt out. Noronha’s flagged heightened volatility for Brazil in the second half, chalking it up to the election cycle. Meanwhile, fallout from the Banco Master affair has put the spotlight back on the FGC, the bank-funded private deposit insurance scheme.
The bank said shareholders and the market would be updated on any significant changes tied to the deal.
